Keywords: adalimumab biologics etanercept psoriasis psoriasis area and severity index switch a b s t r a c t Background: Few studies exist that evaluate the therapeutic response among switchers of tumor necrosis antagonists in patients with psoriasis, especially Asian patients. Objective: This study aimed to evaluate the safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept. Methods: This is a single-center, open-labeled, retrospective study on the effects of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic responses to prior etanercept. We included 13 patients who had received etanercept for at least 3s months but showed inadequate therapeutic response, as defined by less than 50% improvement in psoriasis area and severity index (PASI) 50, compared to baseline after 6 months or less than PASI25 improvement after 3 months in our hospital during 2006e2012. Adalimumab 40 mg was given every other week with a loading dose of 80 mg. Patients were evaluated monthly for safety and effectiveness. PASI, physician global assessment, and scores of scalp lesions were calculated at Weeks 12 and 24. Scalp lesions were assessed separately. Results: At Week 12, one patient (7%) had at least PASI90, two (15%) had at least PASI75, four (31%) had at least PASI50, and eight (61.5%) had at least PASI25 response. At Week 24, two patients (15%) had at least PASI90, three (23%) had at least PASI75, six (46%) had at least PASI50, and nine (69%) had at least PASI25 response. No severe adverse events were recorded in our series. For scalp lesion, adalimumab showed similar efficacy to etanercept nonresponders. Conclusion: Safety profiles of adalimumab were similar to those of etanercept, and PASI50 was achieved in 46% of patients, who failed prior etanercept therapy, after 24 weeks of adalimumab treatment.
Introduction
Both etanercept and adalimumab are tumor necrosis factor (TNF) antagonists that show favorable therapeutic responses in psoriasis and psoriatic arthritis (PsA). However, these two drugs have a slightly different mode of action and treatment response. Few studies exist that evaluate the therapeutic response of psoriasis among the switchers of these two TNF antagonists, especially among Asians. This is a single-center, open-labeled, retrospective study on the effects of adalimumab in patients with moderate-tosevere psoriasis who had inadequate therapeutic responses to prior etanercept.
Methods
We included patients who had received etanercept 25 or 50 mg BIW subcutaneous injection for at least 3 months but showed inadequate therapeutic response, as defined by less than 50% improvement in psoriasis area and severity index (PASI) 50, compared to baseline after 6 months or less than PASI25 improvement after 3 months in our hospital between 2006 and 2012. Patients also met the following national medical insurance reimbursement criteria: (1) age !18 years old with a clinical diagnosis of plaque-type psoriasis vulgaris for more than 6 months, (2) baseline PASI above 10 prior to etanercept and adalimumab injection, (3) psoriasis affecting more than 10% body surface area, and (4) inadequate response, contraindicated or intolerant to narrow-band ultraviolet B or psoralen ultraviolet A phototherapy at least twice a week for 3 months and to at least two of the three conventional systemic agents including methotrexate (up to 15 mg/wk), acitretin, and cyclosporine (up to 5 mg/kg/d).
All included patients received baseline (Week 0) evaluation including age, sex, height, weight, disease duration, previous systemic treatments, reasons for discontinuing systemic treatments, and types of PsA. For evaluation of scalp lesions, signs of scalp psoriasis (erythema, thickness, and scaliness) were scored using a five-point scale (0 ¼ absent; 1 ¼ mild; 2 ¼ moderate; 3 ¼ severe; 4 ¼ very severe). Adalimumab 40 mg injections were given every 2 weeks with a loading dose of 80 mg. Patients were evaluated monthly for safety and effectiveness. PASI, physician global assessment (PGA), and scores of scalp lesions were calculated at Weeks 12 and 24. Patients were also asked to compare the efficacy of etanercept and adalimumab on PsA subjectively at Week 24.
Prior to the treatment, patients were checked for the presence of hepatitis B virus surface antigen, hepatitis C virus (HCV) antibody, and latent tuberculosis (TB) by chest X-ray and Quantiferon TB Gold. Other concomitant major diseases were also recorded.
Results

Demographics
Thirteen patients were enrolled in the study. Baseline demographics were as followed: male-to-female ratio 10:3, mean age 43.1 years (range 25e59 years), mean body mass index (BMI) 26.6, mean psoriatic disease duration 15.1 years (range 0.9e29 years), and all patients having PsA (Table 1) . There were six patients with peripheral arthropathy, four with spondyloarthritis, and three with mixed type. About the comorbidities, two patients were HCV carriers, two were hepatitis B virus (HBV) carriers, and three had multiple comorbidities. All patients received chest X-ray and Quantiferon TB Gold examinations. One patient (Patient 1) had latent TB and was under isoniazid (300 mg/d) prophylaxis therapy for 9 months, according to the local guideline.
Clinical response to etanercept and causes of etanercept discontinuation
Eight patients (Patients 1, 3, 4, 7, 9, 11, 12, and 13) were in the subgroup of primary loss of efficacy or nonresponders. Five patients (Patients 2, 5, 6, 8, and 10) had good response at first but lost therapeutic response later and were listed under secondary loss of efficacy subgroup. Patient 8 had clinical improvement during the first (2 months) and second (6 months) courses of etanercept therapy, but she lost the efficacy during the third course. She too was included in the subgroup of secondary loss of efficacy. Overall, 13 patients were switched to adalimumab therapy due to nonresponse or loss of response, but none for adverse events.
The trend of PASI scores is shown in Figure 1 . PASI scores, PGA scores, and mean PASI reduction are listed in supplement Table 1 . The scalp scores and adverse events are listed in Table 2 .
At Week 12, seven patients (53.8%) had at least PASI25 and two (15%) had at least PASI50. At Week 24, five patients (50%) had at least PASI25 and two (20%) had at least PASI50. (Three patients lacked PASI scores at Week 24.)
Clinical response to adalimumab
At Week 12, one patient (7%) had at least PASI90, two (15%) had at least PASI75, four (31%) had at least PASI50, and eight (61.5%) had at least PASI25 response (the trend of PASI scores is shown in Figure 2 ; PASI scores and PGA scores are shown in supplement Table 2) .
At Week 24, two patients (15%) had at least PASI90, three (23%) had at least PASI75, six (46%) had at least PASI50, and nine (69%) had at least PASI25 response (the trend of PASI scores is shown in Figure 2 ; PASI scores and PGA scores are shown in supplement Table 2 ). Comparing the numbers of at least PASI25 and at least PASI50, the clinical response to adalimumab was found to be better than etanercept at Weeks 12 and 24 in our series.
Mean PASI reduction of patients with primary loss of efficacy was À29.2 at Week 12 and À34.075 at Week 24. Mean PASI reduction of patients with secondary loss of efficacy was À38.92 at Week 12 and À42.26 at Week 24. At Week 12, two patients (25%) in the group of primary loss of efficacy and two (40%) in the group of secondary loss of efficacy achieved at least PASI50 response. At Week 24, three patients (37.5%) in the group of primary loss of efficacy and three (60%) in the group of secondary loss of efficacy achieved at least PASI50 response (Table 3) . Patients with secondary loss of efficacy to etanercept seemed to respond better than those with primary loss of efficacy. However, a definitive conclusion is difficult because of limited number of participants in this case series.
Only one patient (Patient 3) had concomitant oral methotrexate from Week 0 to Week 24 during adalimumab therapy and showed poor response to adalimumab. Other patients received only adalimumab therapy.
Patient 7 had dramatic clinical improvement with mean PASI reduction of À100% at Week 24 compared to that at Week 0 ( Figure 3 ).
Scalp response to adalimumab
Because of the reported good response of etanercept on scalp psoriasis, the effectiveness of both agents on scalp lesions was assessed separately. Ten patients had decreased scores after etanercept treatment despite an inadequate overall PASI response, Figure 1 Trend in PASI scores of etanercept therapy. PASI ¼ psoriasis area and severity index. and seven patients had decreased scores after adalimumab treatment. There was no significant difference between therapeutic efficacies of etanercept and adalimumab on scalp lesions (Table 4) .
Arthralgia response to adalimumab
Most patients reported similar therapeutic effects of etanercept and adalimumab on arthralgia. Three patients (Patients 2, 3, and 6) 
No Methotrexate from Week 0 to Week 24
PASI ¼ psoriasis area and severity index. (Table 4) .
Safety profiles of adalimumab
No severe adverse events were recorded in our series. Only three patients had mild to moderate adverse effects (Patients 1 and 9 had elevated liver function tests and Patient 2 had increased nevi 3 IU/mL) with resistant strain of HBV were found after 3 months of adalimumab therapy, so lamivudine was replaced with adefovir dipivoxil (10 mg every other day) plus lamivudine (100 mg every other day) for the following 6 months until the present time. Patients 9 and 12 patients were undergoing regular follow-ups with liver function blood tests every 3 months and abdomen sonography examinations every 6 months.
Discussion
Although both etanercept and adalimumab are TNF antagonists, they differ in their structures and maybe also in their mode of action. Adalimumab is a fully humanized monoclonal antibody that binds to soluble and membrane-bound TNF-alpha, while etanercept is a fusion protein that binds to soluble TNF-alpha and TNFbeta. Antidrug antibodies have been reported to result in secondary loss of efficacy for adalimumab, but not for etanercept. 1 Results from the pivotal trials show a better PASI75 response of adalimumab compared to etanercept in psoriasis and PsA. 2 However, there are no head-to-head controlled studies to compare the therapeutic efficacy of these two agents in psoriasis or PsA. Failure in adalimumab does not preclude the treatment response of etanercept, and vice versa. Reports on the therapeutic response of etanercept and adalimumab in psoriasis are few in Asia. 19 One retrospective study in One pivotal study of adalimumab in the USA and Canada, which included 147 psoriatic patients, has shown PASI75 response in 53% and 80% of patients taking 40 mg adalimumab every other week and weekly, respectively, at Week 12 after an initial loading dose of 80 mg. 30 Another pivotal study in North America and Germany has shown that 71% psoriatic patients taking 40 mg adalimumab every other week achieve PASI75 response at Week 16. 31 In Japan, one double-blind, placebo-controlled study has shown PASI75 response rates of 62.8% and 57.9% after treatment with adalimumab 40 mg every other week with and without loading dose, respectively, after 16 weeks. 32 Another study from a single community-based hospital in Japan has shown that 81.8% patients receiving adalimumab 40 mg every other week without loading achieve PASI75 response at Week 16. 33 The treatment response is comparable. In Taiwan, although no official trial exists, 66% and 74% patients with mild to moderate psoriasis have achieved subject global assessment score and PGA score of at least marked improvement (greater than 50% improvement) after 12 weeks of adalimumab (40 mg subcutaneously every other week without a loading dose) treatment. 34 The efficacy of switching to a second TNF antagonist after failing the first TNF inhibitor has been studied mostly in patients with rheumatoid arthritis or ankylosing spondylitis. 35e45 In evaluating the effects of biologic switch on patients with psoriasis, primary failure is defined as patients not achieving PASI50 at Week 12 and secondary failure is defined as a loss of response in patients who achieved a PASI50 response at Week 12. In studies that focus on switching from etanercept to adalimumab, as in our study, 80e100% patients achieve at least PASI50 and 33e87% patients achieve at least PASI75 at Week 12, and 83% patients achieve at least PASI50 and 55e83% patients achieve at least PASI75 at Week 24. 4e8 The wide ranges of difference may be explained by differences in washout periods, dosing regimens, baseline severity, prior treatment, and use of concomitant medication. Our results seem to be less impressive compared to the previous reports (Table 5) . Clinical response of psoriasis to both etanercept and adalimumab is less impressive in our series compared to previous reports. The lower PASI75 response in Taiwan reports may be due to the known difference between clinical trials and practical uses. 20, 27 In addition, it may be due to a higher percentage of high-need and recalcitrant patients because of the stringent reimbursement 
criteria in Taiwan. 20, 27 In addition, known differences between human leukocyte antigen found in Taiwan and those found in Western countries may also be important.
46e48
A randomized controlled comparative study (CHAMPION) has shown that the response to adalimumab is rapid with a 57% improvement in mean PASI observed at Week 4. 49 Another phase II/ III randomized controlled study in Japan has also shown that adalimumab has a rapid onset of action (early at 4 weeks), and the percentages of patients achieving PASI75 continue to increase until Week 16 and are maintained through Week 24. 50 However, our series show a trend of increased therapeutic improvement from Week 12 to Week 24. It is likely that longer time is required to achieve full therapeutic response in recalcitrant patients, as in case of our patients. Studies on the effects of biologic switch on patients with psoriasis remain limited in the Asia-Pacific region, and the efficacy of adalimumab after switching from etanercept is of special interest in Taiwan. It is because etanercept was reimbursed for psoriasis 8 months prior to adalimumab. The result of this case series may serve as an important reference for clinicians when considering the next step of treatment after etanercept failure.
Patients who showed inadequate primary response to etanercept also seemed to respond less favorably to subsequent adalimumab treatment. There may be several possible reasons. First, it is likely that other cytokines may be more important in these patients. In fact, recent studies suggest Th17 to be at least as important as TNF in the pathogenic pathway of psoriasis. 51 Second, in one study, non-neutralizing antietanercept antibodies were reported in up to 18% of patients taking etanercept for psoriasis over a period of 96 weeks. 52 However, it is unknown if prior use of etanercept will trigger an increased production of antiadalimumab antibodies. Only one study has shown that patients of rheumatoid arthritis who previously formed antibodies against infliximab are more likely to develop antibodies against adalimumab 53 and that it is more likely that some patients are more prone to develop an immune response, possibly related to the genetic background. In addition, 0.6e12% psoriatic patients would develop antiadalimumab antibodies. 1 It has been found from studies on PsA that antiadalimumab antibodies develop in a minority of patients, and are associated with lower serum levels of adalimumab and diminished clinical response to treatment. 54 Third, the efficacy of anti-TNF antagonists would diminish with time, and the drug survival of patients who previously failed one or more anti-TNF antagonists is more poor compared with the anti-TNF antagonists-naive patients. 55 The scalp is one of the most common sites affected by psoriasis, 56 and scalp psoriasis has a substantial impact on the patients' quality of life. 57 Previous studies have revealed that etanercept exerts impressive therapeutic effects on scalp lesions of psoriasis. 58, 59 Although adalimumab can be effective in patients who are poor responders to etanercept, it is not more effective in those with scalp psoriasis in our case series. The exact reason is unknown, but it is possible that either etanercept has a slightly different mode of action 60 or scalp is an easy target for both agents. For the nonresponders of both agents, a master cytokine other than TNF may be presented. There are no published randomized controlled trials that provide a head-to-head comparison of the effectiveness of the three TNF antagonists (adalimumab, etanercept, and infliximab) in treating patients with PsA.
61e65 Some authors have reported that etanercept might have better effects in controlling PsA. However, in our series, subjective improvement in arthralgia with adalimumab was comparable to that with etanercept. No severe adverse events were recorded in our series, but one HCV carrier and one HBV carrier had elevated liver function tests. An increased risk for HBV carriers has been found in patients with psoriasis in Taiwan. 69 Nevertheless, the use of anti-TNF-alpha therapy for HBV carriers with psoriasis or PsA is still controversial. Due to a lack of consensus in managing HBV carriers with psoriasis or PsA, antiviral prophylaxis is usually used in conjunction with anti-TNF therapy, based on the suggestions for HBV carriers receiving chemotherapeutic agents for their malignancies. 70 However, these patients may develop resistance to antiviral agents, especially lamivudine, during long-term use and show subsequent elevation of aspartate aminotransferase/alanine aminotransferase (AST⁄ALT) levels. 71 In addition, different anti-TNF antagonists may have different impacts on HBV reactivation. Infliximab is associated with more cases of HBV activation compared to etanercept or adalimumab. 72 This may be due to more pronounced clearance of TNF-a, as the drug binds both soluble and membrane-bound TNF-a and is also cytotoxic for TNF-expressing cells. 73 But there are no data comparing between the impact of etanercept and adalimumab on HBV. The increased HBV viral load after switching from etanercept to adalimumab in our patient might be due to either a time factor after prolonged antiviral treatment or a stronger immunosuppressive effect of adalimumab. However, it seems safe to use adalimumab for treating psoriatic patients who are HBV carriers under closer monitoring.
Conclusion
This is a preliminary report of our experience of reimbursed adalimumab use for psoriasis in Taiwan. This study was limited by the relatively short study duration and small sample size. A national registry of all biologic users is needed to assess the safety and efficacy of adalimumab. However, long-term results are unlikely to be gathered from this registry because of the strict reimbursement criteria in Taiwan, which necessitate discontinuation of biologics after 6e12 months for the PASI50 responders. Adalimumab has similar safety profiles as etanercept and can be effective in some psoriatic patients who have failed prior etanercept therapy.
